Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a depression drug tame COVID-19 immune overreaction?

NCT ID NCT04590222

Knowledge-focused Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study tested whether phenelzine, a drug used for depression, could change how immune cells behave in people with COVID-19. Researchers took blood samples from 51 patients and exposed the cells to phenelzine in the lab. The goal was to see if the drug could reduce overactive immune responses, but this was a basic science study, not a treatment trial.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
phenelzine
What this could lead to
If successful, this could point toward ways to modulate the immune system in COVID-19, but it is a very early, small study focused on lab findings, not a treatment.
What could go wrong
This is a tiny, completed lab study with only 51 participants. It only looked at blood samples in a dish, not actual treatment in patients. Results may not lead to any real-world therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

51 people

The number who actually took part.

Started

Nov 2020

Finished

Jan 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients will be recruited from the Bicêtre Hospital (followed in hospitalization and in ambulatory services)

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 1\. Individuals male or female ≥18 years of age at time of enrolment * 2.Subject (or legally authorized representative provides non opposition form prior to initiation of any study procedure. * 3\. Understands and agrees to comply with planned study procedure. (Agrees to the collection of venous blood per protocol). * 4\. Has laboratory-confirmed SARS-CoV-2 infection as determined by PCR, or other commercial or public health assay in any specimen\<72hours prior to enrollment and/or a chest CT scan reported as highly likely SARS-CoV2 infection. The different scales for severity are as follows: * 5\. Non severe patients: Clinical assessment (evidence of rales/crackles on exam) or CT scan involvement AND SpO2\> 94% on room air, or ≤ 94% on room air but \> 94% with nasal Oxygen with a flow rate \<= 3l O2/min For the severe infection's patients' group: * 6\. Patients requiring mechanical ventilation and/or supplemental oxygen \>= 6l O2/min For the obese patients 'group: * 7\. Obese patients will be defined as an BMI \> 30 * 8\. Co inclusion in non-interventional researches is possible Exclusion Criteria: * Pregnant and breast-feeding women * Patients previously treated by phenelzine (Nardil®) * Persons unable to give their no opposition * Persons under guardianship or curatorship * No affiliated to social insurance. * Inclusion in interventional researches

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SARS-COV2 infection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SARS-COV2 infection

Contacts and locations

Locations

  • CHU Bicêtre

    Le Kremlin-Bicêtre, 94270, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.